Tessa Therapeutics Ltd

Tessa Therapeutics Ltd is a clinical-stage biotechnology company based in Singapore, focused on developing next-generation cell therapies for hematological cancers and solid tumors.

The company specializes in cancer immunotherapy, utilizing approaches such as CD30-CAR therapies and Virus-Specific T Cells (VSTs). Tessa's capabilities include research, clinical development, and commercialization of these innovative therapies. The company has developed several key products, including TT11, an autologous CD30-CAR-T therapy for relapsed or refractory classical Hodgkin lymphoma, and TT11X, an allogeneic CD30-CAR EBVST platform for CD30-positive lymphomas. Additionally, Tessa is working on the TT16 program, which targets HER2-positive cancers. Its pipeline also addresses various other cancers, including nasopharyngeal, cervical, oropharyngeal, lung, breast, bladder, and head and neck cancers.